ALPN — Alpine Immune Sciences Balance Sheet
0.000.00%
Last trade - 00:00
- $2.58bn
- $2.25bn
- $58.88m
- 49
- 13
- 100
- 54
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 40.5 | 106 | 162 | 238 | 327 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.686 | 0.388 | 25.3 | 0.709 | 0.749 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 42.3 | 107 | 192 | 241 | 330 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 11.5 | 11.2 | 10.6 | 9.8 | 8.99 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 54.1 | 144 | 256 | 287 | 380 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 8.68 | 41.2 | 69.8 | 58 | 42 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 24.6 | 81.9 | 135 | 107 | 51.9 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 29.5 | 62.2 | 121 | 179 | 328 |
Total Liabilities & Shareholders' Equity | 54.1 | 144 | 256 | 287 | 380 |
Total Common Shares Outstanding |